Can a Physician Be Assessed Punitive Damages for Altering or Destroying Medical Records?

By November 13, 2018

During her testimony, Dr E was asked about the notes in the chart, and she was forced to admit that she transcribed the scribble notes into the patient's record after the patient died and she had been contacted by the plaintiff's law firm asking for the records.

Direct-Acting Antiviral Therapy Linked to Reduced Risk of Incident T2D in HCV Patients

By November 13, 2018

The study compared US administrative claims data of HCV patients with ≥12 weeks of dispensed DAA therapy (N=17,848) to untreated HCV patients with follow-up data (N=108,350).

Empagliflozin Effectively Reduces Risk for Heart Failure Hospitalization

November 11, 2018

Approximately 50% of deaths in people with type 2 diabetes worldwide, and approximately two-thirds of deaths in people with type 2 diabetes in the US are caused by cardiovascular disease.

CDC: About One in Three Adults With Prediabetes Has Arthritis

November 09, 2018

The unadjusted prevalence rates of leisure-time physical inactivity and obesity were 56.5 and 50.1%, respectively, among adults with both arthritis and prediabetes.

Hypoglycemia Following Antifungal Tx in Patient With Type 1 Diabetes

By November 07, 2018

"This is the first report of decreased insulin requirements in a patient with T1DM correlating with micafungin administration," noted the authors.

Aggressive Control of BP, Lipids in T2DM May Up Kidney Risk

November 02, 2018

"We believe that the data actually suggest possible benefit for ESKD [end-stage kidney disease] with intensive glucose control, and remain inconclusive for intensive blood pressure control and fibrate use given the wide confidence intervals for the more reliable ESKD outcomes," write the authors.

Plant-Based Diets Better for T2D Than Several Official Diabetes Guidelines

November 02, 2018

Researchers found that, compared with several diabetes associations' official guidelines and other comparator diets, plant-based diets were correlated with significant improvements in emotional well-being, physical well-being, depression, and quality of life.

Invokana Approved to Reduce Risk of Major Adverse Cardiovascular Events

By October 30, 2018

The effect of Invokana on CV risk was evaluated in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program in >10,000 adults with T2D who had established CV disease or were at risk for CV disease with ≥2 risk factors.

Ready-to-Use Glucagon Rescue Pen Under FDA Review for Severe Hypoglycemia Tx

By October 23, 2018

The NDA included findings from multiple Phase 3 trials evaluating the safety, efficacy, and utility of the Xeris glucagon rescue pen auto-injector to treat severe hypoglycemia vs currently available glucagon emergency kits in children, adolescents, and adults with type 1 diabetes.

Saxenda Labeling Updated With Cardiovascular Safety Data

By October 23, 2018

The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non-fatal stroke, CV death) in patients treated with liraglutide 1.8mg once daily or placebo.

Abatacept May Reduce Diabetes Risk in Rheumatoid Arthritis

October 23, 2018

The researchers concluded their findings indicate that for patients with RA, abatacept reduced the risk for diabetes and "potentially improved insulin sensitivity and glycemic profile."

Gastric Banding, Metformin Assessed for Glycemia Improvements

October 16, 2018

The researchers found that at 24 months, the band group lost 10.7kg and the metformin group lost 1.7kg (P<.01). Furthermore, in the band group, insulin sensitivity increased 45% compared with 25% in the metformin group (P=.3 between groups).

Cases Show Periodic Fasting May Cut Medication Use in T2DM

October 15, 2018

Discontinuation of insulin, other diabetes medications seen in case series of three patients

High Circulating Prolactin Level Inversely Linked to T2DM Risk

October 12, 2018

During the first 9 years after blood draw, the inverse association of total prolactin with type 2 diabetes was significant but waned linearly with time; for bioactive prolactin, the inverse association persisted for longer after blood draw.

ADA, EASD Issue New Recommendations for Type 2 Diabetes

October 10, 2018

Efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended for those with obesity. A sodium-glucose cotransporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended for patients with clinical cardiovascular disease.

Empagliflozin Impact on Life Expectancy Examined in T2DM Patients With CVD

By October 10, 2018

For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.

Lixisenatide Cuts Kidney Damage in T2DM and Coronary Syndrome

October 05, 2018

Patients with type 2 diabetes and a recent coronary artery event were randomized to a daily subcutaneous injection of lixisenatide or volume-matched placebo in addition to usual care.

Positive Results for Empagliflozin in Type 1 Diabetes Trials

By October 05, 2018

The EASE Phase 3 program included 2 double-blind, placebo-controlled trials investigating the efficacy and safety of empagliflozin as an adjunct to insulin therapy in adults with type 1 diabetes.

Lorcaserin Reduces Risk of Incident Diabetes in Patients With Prediabetes

By October 05, 2018

In this new analysis, researchers looked at the long-term effects of the drug on diabetes prevention and remission in these patients.

Albiglutide Associated With Fewer Cardiovascular Events vs Placebo in T2DM

October 04, 2018

Noting that in 2017, GlaxoSmithKline withdrew the glucagon-like peptide 1 (GLP-1) receptor agonist albiglutide for commercial reasons, Adrian F. Hernandez, MD, from the Duke University School of Medicine in Durham, NC, and colleagues presented the results from a randomized multicenter international trial involving albiglutide.

High HbA1c After T1DM Diagnosis Predicts Psychiatric Comorbidity

October 03, 2018

Higher risk for psychiatric diagnoses was predicted by high average HbA1c levels during the first 2 years of diabetes onset.

FDA Issues Safety Communication Regarding Pen Needle Use

By October 03, 2018

Standard pen needles have an outer cover and removable inner needle cover, while safety pen needles have an outer cover and a fixed inner needle shield that is not removed before an injection.

Study Provides Estimates of US Prevalence of Type 1, 2 Diabetes

September 21, 2018

The researchers found that 6317 adults received a diagnosis of diabetes. Among US adults, the weighted prevalence of diagnosed diabetes, type 1 diabetes, and type 2 diabetes was 9.7, 0.5, and 8.5%, respectively.

Gestational Diabetes Tied to Subsequent Glucose Disorders

September 20, 2018

"Gestational diabetes defined by criteria that identify a larger group of women was associated with a maternal disorder of glucose metabolism," the authors write.

FDA to Review Eylea for the Treatment of Non-Proliferative Diabetic Retinopathy

By September 14, 2018

The sBLA includes results from the Phase 3 PANORAMA trial, which enrolled 402 patients with NPDR.

Reducing HF Hospitalization Risk: Antidiabetic Drug Classes Compared

By September 11, 2018

The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.

Cost a key consideration of WHO guidelines for diabetes treatment intensification

September 06, 2018

WHO guidelines recommend selecting sulfonylureas as the single best second-line agent for Type 2 Diabetes Mellitus (T2DM) patients.

WHO Issues Recommendations for Tx Intensification in T2DM

September 05, 2018

"The decision to name sulfonylureas as the single best second-line agent largely reflects the prioritization of cost and the recognition that WHO guidelines must apply to low-resource settings," write the authors of an accompanying editorial.

FDA: Cases of Rare Gangrene of Genital Area Tied to Diabetes Drug Class

By August 30, 2018

The infection developed within several months of the patients starting SGLT2 therapy and the drug was discontinued in most cases. All patients required surgery and there was 1 reported death.

Increased First-Trimester HbA1c Predicts Gestational Diabetes

August 24, 2018

The researchers found that women who later developed GDM had significantly higher HbA1c at 8 to 13 gestational weeks than women without GDM (5.3 vs 5.1%).